Ankylosing spondylitis lumbar region
ICD-10 M45.6 is a billable code used to indicate a diagnosis of ankylosing spondylitis lumbar region.
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the axial skeleton, leading to pain and stiffness in the spine and sacroiliac joints. The lumbar region is often involved, resulting in significant discomfort and reduced mobility. AS is characterized by inflammation of the entheses, the sites where tendons and ligaments attach to bone, which can lead to new bone formation and eventual fusion of the vertebrae. Patients may experience acute episodes of back pain, which can improve with physical activity but worsen with rest. The condition is more prevalent in males and typically presents in late adolescence or early adulthood. Diagnosis is often supported by imaging studies showing sacroiliitis and the presence of the HLA-B27 antigen. Management includes physical therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), and biologic therapies targeting tumor necrosis factor (TNF) or interleukin-17 (IL-17).
Detailed history of symptoms, physical examination findings, imaging results, and treatment plans.
Initial diagnosis of AS, management of flare-ups, and monitoring of disease progression.
Ensure documentation reflects the inflammatory nature of the condition and any associated comorbidities.
Surgical notes if applicable, imaging studies, and pre-operative assessments.
Surgical intervention for severe spinal deformities or complications from AS.
Document any functional limitations and the impact on daily activities.
Used for initial assessment of functional limitations in AS patients.
Detailed evaluation of physical function and pain levels.
Rheumatologists may refer patients for therapy to improve mobility.
The primary symptom is chronic pain and stiffness in the lower back and hips, particularly in the morning or after periods of inactivity.
Diagnosis is based on clinical symptoms, physical examination, imaging studies showing sacroiliitis, and the presence of the HLA-B27 antigen.
Treatment options include NSAIDs, physical therapy, and biologic medications targeting inflammation.
